BACKGROUND: Numerous studies have demonstrated that expression of estrogen/progesterone receptor (ER/PR) and human epidermal growth factor receptor (HER)-2 is important for predicting overall survival (OS), distant relapse (DR), and locoregional relapse (LRR) in early and advanced breast cancer patients. However, these findings have not been confirmed for inflammatory breast cancer (IBC), which has different biological features than non-IBC. METHODS: We retrospectively analyzed the records of 316 women who presented to MD Anderson Cancer Center in 1989-2008 with newly diagnosed IBC without distant metastases. Most patients received neoadjuvant chemotherapy, mastectomy, and postmastectomy radiation. Patients were grouped according to receptor status: ER(+) (ER(+)/PR(+) and HER-2-; n = 105), ER(+)HER-2(+) (ER(+)/PR(+) and HER-2(+); n = 37), HER-2(+) (ER(-)/PR(-) and HER-2(+); n = 83), or triple-negative (TN) (ER(-)PR(-)HER-2(-); n = 91). Kaplan-Meier and Cox proportional hazards methods were used to assess LRR, DR, and OS rates and their associations with prognostic factors. RESULTS: The median age was 50 years (range, 24-83 years). The median follow-up time and median OS time for all patients were both 33 months. The 5-year actuarial OS rates were 58.7% for the entire cohort, 69.7% for ER(+) patients, 73.5% for ER(+)HER-2(+) patients, 54.0% for HER=2(+) patients, and 42.7% for TN patients (p < .0001); 5-year LRR rates were 20.3%, 8.0%, 12.6%, 22.6%, and 38.6%, respectively, for the four subgroups (p < .0001); and 5-year DR rates were 45.5%, 28.8%, 50.1%, 52.1%, and 56.7%, respectively (p < .001). OS and LRR rates were worse for TN patients than for any other subgroup (p < .0001-.03). CONCLUSIONS: TN disease is associated with worse OS, DR, and LRR outcomes in IBC patients, indicating the need for developing new locoregional and systemic treatment strategies for patients with this aggressive subtype.
BACKGROUND: Numerous studies have demonstrated that expression of estrogen/progesterone receptor (ER/PR) and humanepidermal growth factor receptor (HER)-2 is important for predicting overall survival (OS), distant relapse (DR), and locoregional relapse (LRR) in early and advanced breast cancerpatients. However, these findings have not been confirmed for inflammatory breast cancer (IBC), which has different biological features than non-IBC. METHODS: We retrospectively analyzed the records of 316 women who presented to MD Anderson Cancer Center in 1989-2008 with newly diagnosed IBC without distant metastases. Most patients received neoadjuvant chemotherapy, mastectomy, and postmastectomy radiation. Patients were grouped according to receptor status: ER(+) (ER(+)/PR(+) and HER-2-; n = 105), ER(+)HER-2(+) (ER(+)/PR(+) and HER-2(+); n = 37), HER-2(+) (ER(-)/PR(-) and HER-2(+); n = 83), or triple-negative (TN) (ER(-)PR(-)HER-2(-); n = 91). Kaplan-Meier and Cox proportional hazards methods were used to assess LRR, DR, and OS rates and their associations with prognostic factors. RESULTS: The median age was 50 years (range, 24-83 years). The median follow-up time and median OS time for all patients were both 33 months. The 5-year actuarial OS rates were 58.7% for the entire cohort, 69.7% for ER(+) patients, 73.5% for ER(+)HER-2(+) patients, 54.0% for HER=2(+) patients, and 42.7% for TNpatients (p < .0001); 5-year LRR rates were 20.3%, 8.0%, 12.6%, 22.6%, and 38.6%, respectively, for the four subgroups (p < .0001); and 5-year DR rates were 45.5%, 28.8%, 50.1%, 52.1%, and 56.7%, respectively (p < .001). OS and LRR rates were worse for TNpatients than for any other subgroup (p < .0001-.03). CONCLUSIONS:TN disease is associated with worse OS, DR, and LRR outcomes in IBC patients, indicating the need for developing new locoregional and systemic treatment strategies for patients with this aggressive subtype.
Authors: Z Liao; E A Strom; A U Buzdar; S E Singletary; K Hunt; P K Allen; M D McNeese Journal: Int J Radiat Oncol Biol Phys Date: 2000-07-15 Impact factor: 7.038
Authors: C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein Journal: Nature Date: 2000-08-17 Impact factor: 49.962
Authors: Joel S Parker; Michael Mullins; Maggie C U Cheang; Samuel Leung; David Voduc; Tammi Vickery; Sherri Davies; Christiane Fauron; Xiaping He; Zhiyuan Hu; John F Quackenbush; Inge J Stijleman; Juan Palazzo; J S Marron; Andrew B Nobel; Elaine Mardis; Torsten O Nielsen; Matthew J Ellis; Charles M Perou; Philip S Bernard Journal: J Clin Oncol Date: 2009-02-09 Impact factor: 44.544
Authors: Maggie C U Cheang; Stephen K Chia; David Voduc; Dongxia Gao; Samuel Leung; Jacqueline Snider; Mark Watson; Sherri Davies; Philip S Bernard; Joel S Parker; Charles M Perou; Matthew J Ellis; Torsten O Nielsen Journal: J Natl Cancer Inst Date: 2009-05-12 Impact factor: 13.506
Authors: Julie S Wecsler; Welela Tereffe; Rose C Pedersen; Michelle R Sieffert; Wendy J Mack; Haiyan Cui; Christy A Russell; Ryan R Woods; Rebecca K Viscusi; Stephen F Sener; Julie E Lang Journal: Breast Cancer Res Treat Date: 2015-04-07 Impact factor: 4.872
Authors: H Masuda; T M Brewer; D D Liu; T Iwamoto; Y Shen; L Hsu; J S Willey; A M Gonzalez-Angulo; M Chavez-MacGregor; T M Fouad; W A Woodward; J M Reuben; V Valero; R H Alvarez; G N Hortobagyi; N T Ueno Journal: Ann Oncol Date: 2013-12-18 Impact factor: 32.976
Authors: Jieqiong Liu; Kai Chen; Wen Jiang; Kai Mao; Shunrong Li; Min Ji Kim; Qiang Liu; Lisa K Jacobs Journal: J Cancer Res Clin Oncol Date: 2016-10-04 Impact factor: 4.553
Authors: Nataliya Babyshkina; Elena Malinovskaya; Stanislav Patalyak; Olga Bragina; Natalia Tarabanovskaya; Artem Doroshenko; Elena Slonimskaya; Vladimir Perelmuter; Nadejda Cherdyntseva Journal: Med Oncol Date: 2014-08-20 Impact factor: 3.064
Authors: Angie M Torres-Adorno; Jangsoon Lee; Takahiro Kogawa; Peter Ordentlich; Debu Tripathy; Bora Lim; Naoto T Ueno Journal: Clin Cancer Res Date: 2017-05-02 Impact factor: 12.531
Authors: Kevin P Williams; Jennifer L Allensworth; Shalonda M Ingram; Ginger R Smith; Amy J Aldrich; Jonathan Z Sexton; Gayathri R Devi Journal: Cancer Lett Date: 2013-05-17 Impact factor: 8.679
Authors: Chiaojung Jillian Tsai; Jing Li; Ana M Gonzalez-Angulo; Pamela K Allen; Wendy A Woodward; Naoto T Ueno; Anthony Lucci; Savitri Krishnamurthy; Yun Gong; Wei Yang; Massimo Cristofanilli; Vicente Valero; Thomas A Buchholz Journal: Am J Clin Oncol Date: 2015-06 Impact factor: 2.339